Bridging Science to Life
JN Biosciences LLC
320 Logue Avenue
Mountain View, CA 94043
May 28, 2020
A phase 2 clinical study with a humanized anti-TIGIT IgG1 monoclonal antibody (AB154, domvanalimab) sponsored by Arcus Biosciences for treatment of non-small cell lung cancer was initiated (NCT04262856). The title of the study is "Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)."
January 21, 2020
A U.S. Patent entitled "Antibodies to TIGIT" (US10537633), on which JN Biosciences' J Yun Tso and Naoya Tsurushita are inventors, was issued.
Copyright 2022 JN Biosciences. All rights reserved.
JN Biosciences LLC
320 Logue Avenue
Mountain View, CA 94043